Clinical trials: Art Therapy
HIV Infections, AIDS
DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release (d4T XR), lamivudine (3TC), and efavirenz (EFV) leads to improved outcomes, as measured by viral load, CD4…
- Trial name
- NCT00116116
- Testing
- efavirenz, stavudine extended release, lamivudine
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
HIV Infections
The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give calanolide A to HIV-infected adults who have not used anti-HIV drugs in the past.
- Trial name
- NCT00005120
- Testing
- Calanolide A
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sarawak MediChem Pharmaceuticals
Stress Reduction, Psychological Wellbeing
The Concert Therapy Pilot Study for Stress Reduction and Wellbeing
The Concert Therapy is an arts-based, pilot interventional study designed to explore the effects of live music, guided breathing, and movement on stress reduction and overall wellbeing.
- Conditions
- Stress Reduction, Psychological Wellbeing, Mental Health, Music Therapy
- Trial name
- TCT (NCT07236918)
- Testing
- The Concert Therapy
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- BeHnam KhodaRahmi
Malaria
Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks
Primary objective is to demonstrate the non-inferiority of PCR (Polymerase Chain Reaction) adjusted adequate clinical and parasitological response at Day 28 of Coarsucam versus Coartem, based on the first malaria attack of each…
- Trial name
- SMART-CURE (NCT00699920)
- Testing
- Coarsucam, Coartem
- Where
- Uganda
- Volunteers
- 413 people
- Sponsor
- Sanofi
HIV Infections
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.
- Trial name
- NCT00009061
- Testing
- Ritonavir, Abacavir sulfate, Nelfinavir mesylate
- Where
- 37 sites in United States
- Volunteers
- 624 people
- Sponsor
- Glaxo Wellcome
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection
ICVAX as a HIV Therapeutic DNA Vaccine
The clinical trial is a dose-escalation, randomized, double-blind, placebo-controlled phase I study at a single center to evaluate the safety, tolerability and immunogenicity of HIV Therapeutic DNA Vaccine, ICVAX, in clinically…
- Trial name
- NCT06253533
- Testing
- ICVAX
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Immuno Cure Holding (HK) Limited
HIV Infections
A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment
The purpose of this study is to test the safety and effectiveness of a new non-nucleoside reverse transcriptase inhibitor (NNRTI), (+)-calanolide A, in HIV-positive patients who have never received anti-HIV treatment.
- Trial name
- NCT00002243
- Testing
- Calanolide A
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sarawak MediChem Pharmaceuticals
HIV Infections
Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations
The purpose of this study is to see if it is safe and effective to give adefovir plus other anti-HIV drugs to HIV-infected patients who have failed other anti-HIV drug combinations.
- Trial name
- NCT00002398
- Testing
- Levocarnitine, Adefovir dipivoxil
- Where
- United States
- Sponsor
- Gilead Sciences
HIV Infection
Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)
PHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with…
- Trial name
- PHPC-02 (NCT00918840)
- Testing
- DermaVir, HAART
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Genetic Immunity
HIV Infections, Human Immunodeficiency Virus
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients
This is a 28-day, multi-center, placebo-controlled study designed to look at the dose response, efficacy, and safety of SP01A, given as a pill to be swallowed, in the treatment of HIV-infected subjects.
- Trial name
- NCT00299897
- Testing
- SP01A
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Samaritan Pharmaceuticals, Inc
HIV Infections
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
The purpose of this study is to see if it is safe and effective to give HIV-positive patients L2-7001 (a type of interleukin-2) plus anti-HIV therapy.
- Trial name
- NCT00002449
- Testing
- Aldesleukin
- Where
- 23 sites in United States
- Volunteers
- 212 people
- Sponsor
- Chiron Corporation
Infection, Human Immunodeficiency Virus I, HIV Infection
GW873140 In Combination With Kaletra In HIV Infected Subjects
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.
- Trial name
- NCT00102778
- Testing
- GW873140, Kaletra (lopinavir/ritonavir)
- Where
- 70 sites in United States, Canada and 8 more
- Volunteers
- 175 people
- Sponsor
- ViiV Healthcare
HIV Infections
Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients
Primary Objectives 1.Evaluation of safety and tolerability after repeated administration of injectable Lipivirtide in HIV-infected patients not receiving antiretroviral therapy Secondary Objectives 1.
- Trial name
- NCT05349968
- Testing
- Lipovirtide for injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
Arthritis, Rheumatoid, Osteo Arthritis
A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis
This study will evaluate the safety and tolerability of a single intra-articular administration of ART-I02 (AAV5.NF-kB.IFN-β), a recombinant adeno-associated virus (AAV) type 2/5 vector in subjects with Rheumatoid Arthritis (RA)…
- Trial name
- NCT02727764
- Testing
- ART-I02
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Arthrogen
HIV -1 Infection
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry.
- Trial name
- VISTA (NCT07215468)
- Testing
- TMB-365, TMB-380, Baseline ART
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- TaiMed Biologics Inc.
HIV, HIV-1
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have…
- Conditions
- HIV, HIV-1, Human Immunodeficiency Virus
- Trial name
- NCT00298350
- Testing
- GS-9137 - A Novel HIV-1 Integrase Inhibitor
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 278 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
CIN 2/3, HPV Infection
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia
- Trial name
- ART-CIN_IIB (NCT04098744)
- Testing
- Artesunate vaginal insert
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Frantz Viral Therapeutics, LLC